After Warning Letter, a recall for Hospira injectables

By Fiona Barry

- Last updated on GMT

The recall follows a Warning Letter sent in September. (Image: Lamoix)
The recall follows a Warning Letter sent in September. (Image: Lamoix)

Related tags: Saudi arabia

Hospira has recalled ten lots of injectable Mitoxantrone it says are subpotent and contain impurities.

Mitoxantrone is an anthracenedione antineoplastic agent used in oncology. Affected batches were manufactured from March 2014 onwards.

Injectables with decreased potency can lead to decreased effectiveness, additional dosing and the potential for cumulative impurity toxicity requiring medical intervention, the company said.

The drug was distributed for human and veterinary use in North America, Australia, New Zealand, the UK, Ireland, Cyprus, and the Middle East.

Hospira said it has identified the root cause of the batch faults.

Plant problems

Mitoxantrone is manufactured at Hospira’s site in Mulgrave Australia. The plant received a Warning Letter from the FDA in September 2014​ because of unknown impurity levels in batches of the cancer drug.

The FDA wrote Hospira had “failed to thoroughly investigate unexplained discrepancies or failures of a batch​” after stability studies on several batched of Mitoxantrone injections showed impurities.

The regulator added it was “concerned that you do not know the actual levels of this impurity in distributed lots of Mitoxantrone Injection.​”

The drugmaker did not tell in-Pharmatechnologist.com the reason for a delay between the Warning Letter on September 26 and the launch of the Mitoxantrone recall on December 23.

The voluntary recall affects the following lots:

US

MitoXANTRONE Injection, USP, (concentrate) 20 mg/10 mL, 2 mg/mL in 10 mL, 10 mL Vial, Multi Dose Vial, Lots Z054636AA, A014636AA, and A024636AB;

Australia and New Zealand

MitoXANTRONE Injection, USP, (concentrate) 25 mg/12.5 mL, 2 mg/mL in 12.5 mL, 12.5 mL Vial, Multi Dose Vial, Lot A014643AA;

Canada

MitoXANTRONE for Injection 20mg /10mL USP, Lot A024636AC;

UK, Ireland, Cyprus, Saudi Arabia, Qatar, Oman and Bahrain

MitoXANTRONE 2 mg/mL; Concentrate for Infusion, Lot A014636AB, A024636AD, and Z054636AB.

Related topics: Markets & Regulations, QA/QC, Regulations

Related news

Show more

Related products

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Related suppliers

Follow us

Products

View more

Webinars